Participant flow15

How many started, completed or left each group, period by period.

1 to 15 of 15

Period	Milestone	Group	Participants
Overall Study	STARTED	Ertugliflozin 5 mg	448
Overall Study	STARTED	Ertugliflozin 15 mg	441
Overall Study	STARTED	Glimepiride	437
Overall Study	Treated	Ertugliflozin 5 mg	448
Overall Study	Treated	Ertugliflozin 15 mg	440
Overall Study	Treated	Glimepiride	437
Overall Study	Site Issue	Ertugliflozin 5 mg	445
Overall Study	Site Issue	Ertugliflozin 15 mg	435
Overall Study	Site Issue	Glimepiride	435
Overall Study	COMPLETED	Ertugliflozin 5 mg	339
Overall Study	COMPLETED	Ertugliflozin 15 mg	340
Overall Study	COMPLETED	Glimepiride	327
Overall Study	NOT COMPLETED	Ertugliflozin 5 mg	109
Overall Study	NOT COMPLETED	Ertugliflozin 15 mg	101
Overall Study	NOT COMPLETED	Glimepiride	110

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01999218/flow